Sagent Reintroduces Adenosine Injection With Improved Prefilled Plastic Syringes

Sagent Pharmaceuticals has reintroduced Adenosine Injection, USP, an antiarrhythmic agent, with improved prefilled plastic syringes. For the 12 months ending February 2014, the U.S. market for Adenosine Injection, USP approximated $28 million.
Pharmaceutical Business Review